Moffitt Cancer Center’s Health and Research Informatics Platform
The overall research goals for Moffitt’s Health & Research Informatics (HRI) platform are to establish a flexible data integration and management platform to support clinical, molecular, and epidemiological research, provide administrative dashboards for decision support, and, at the point of care, provide clinicians and patients with treatment options and their comparative effectiveness. The HRI currently includes data for approximately 400,000 patients who underwent cancer screening and/or treatment at Moffitt Cancer Center. Types of clinical information currently available in HRI include cancer diagnosis, stage, chemotherapy, radiation therapy, surgery, hormonal therapy, demographics, comorbidities, clinical lab values, performance status, disease status, and survival. Patient self-reported data include information on smoking, alcohol, physical activity, diet, medication use, review of systems, use of complementary and alternative medicine, quality of life and other psychosocial factors. Information on the availability of blood and tumor tissues, and associated gene expression profiles, is also included in HRI. All of these data are can be queried by end users in their de-identified form, with identified data provided by a certified honest broker to requestors with appropriate regulatory approvals.
EHR/EMR System or Vendor
Primary care or ambulatory clinics, Inpatient facilities, Academic medical centers
Electronic Health/Medical Records (EHR or EMR), Diagnostic data, Pharmacy databases, Claims, Patient Registries, Patient-Reported Outcomes, Data Collected for Independent, Research Studies (e.g. clinical trial, longitudinal outcomes study)
Geographic scope type
Locations of Focus
the Tampa Bay region, Florida, the southeastern US
Population Network Size
The HRI currently includes data for approximately 400,000 patients who underwent cancer screening and/or treatment at Moffitt Cancer Center. A subset of approximately 60,000 patients have consented to Moffitt Cancer Center’s Total Cancer Care™ protocol. Patients participating in Moffitt’s Total Cancer Care (TCC) protocol consents to the banking of their tumor tissues and use of their clinical data for research purposes, in addition to being followed for clinical outcomes over time and potentially being recontacted if they are identified as being eligible for a new clinical trial. As part of the protocol, MCC has established a biospecimen bank, including tumor tissues for which molecular signatures are obtained for biomarker-driven matching to specific clinical trials. Assets of the TCC protocol include: • Patient consenting process for longitudinal follow up and donation of clinical specimens • Biobanking facility • Collection of self-reported patient data • Health and research informatics (HRI) platform Data collected from patients consented to the TCC protocol are integrated with EMR data within Moffitt’s Health & Research Informatics (HRI) platform.
The Moffitt HRI is built on the Oracle Health Sciences Enterprise Healthcare Analytics platform. Informatica’s PowerCenter is used to write ETL, with Transmed’s XB Bio-integration Suite serving as the front-end querying tool.
The major partners involved with the initial build of HRI included Oracle, Deloitte and TransMed.
CER/PCOR Study Priority Populations
Women, The elderly, Individuals who need chronic care, Individuals who need end-of-life care, Cancer
Cancer treatments include chemotherapy, radiation therapy, surgery, hormonal therapy, immunotherapy and bone marrow transplant. When comparing clinical outcomes between different treatment groups, important confounders to consider include age, stage at diagnosis, smoking status, presence of comorbidities, and performance status.
Outcome(s) of Interest
cancer recurrence, performance status, quality of life second primary malignancies and overall survival.